Exagen (NASDAQ:XGN) Announces Earnings Results

Exagen (NASDAQ:XGN) announced its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02, Zacks reports. Exagen had a negative return on equity of 84.26% and a negative net margin of 30.36%. The company had revenue of $12.51 million during the quarter, compared to the consensus estimate of $13.55 million. During the same period in the previous year, the company posted ($0.31) earnings per share. Exagen updated its FY 2024 guidance to EPS.

Exagen Trading Up 1.8 %

Shares of XGN traded up $0.05 during midday trading on Wednesday, reaching $2.84. The company had a trading volume of 11,178 shares, compared to its average volume of 41,810. Exagen has a 1-year low of $1.30 and a 1-year high of $3.71. The firm has a 50 day simple moving average of $2.84 and a 200-day simple moving average of $2.37. The company has a quick ratio of 4.32, a current ratio of 4.32 and a debt-to-equity ratio of 1.13.

Analyst Ratings Changes

Separately, William Blair restated an “outperform” rating on shares of Exagen in a report on Wednesday.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).